Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)
Phase 2 Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer
Sponsor: Peking University Cancer Hospital & Institute
A PHASE2 clinical study on Small Cell Lung Cancer Extensive Stage, this trial is ongoing. The trial is conducted by Peking University Cancer Hospital & Institute and has accumulated 7 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .